Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Case Series.
muscle mass
muscle strength
ovarian cancer
sarcopenia
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
17
07
2024
received:
13
03
2024
accepted:
19
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
ppublish
Résumé
In ovarian and other cancers, low muscle mass and density are associated with poorer clinical outcomes. However, screening for cancer-related sarcopenia (typically defined as low muscle mass) is not routinely conducted. The European Working Group on Sarcopenia in Older People (EWGSOP) recommends an algorithm for sarcopenia screening and diagnosis in clinical settings, with sarcopenia based on muscle strength and mass, and severity on physical performance. We explored the application of the EWGSOP2 algorithm to assess sarcopenia in six ovarian cancer patients receiving neoadjuvant chemotherapy. We assessed sarcopenia risk with the SARC-F screening questionnaire (at risk ≥4 points), muscle strength with a handgrip strength test (cut point <16 kg) and five times sit-to-stand test (cut point >15 s), muscle mass by skeletal muscle index (SMI in cm Of six participants, none were identified as "at risk" for sarcopenia based on SARC-F scores. Two participants were severely sarcopenic based on EWGSOP2 criteria (had low muscle strength, mass, and physical performance), and five participants were sarcopenic based on muscle mass only. Ovarian cancer patients with low muscle mass during neoadjuvant chemotherapy may not be identified as sarcopenic based on the EWGSOP2 diagnostic algorithm. While lacking a universally accepted definition for cancer-related sarcopenia and cancer-specific recommendations for the screening, diagnosis, and treatment of sarcopenia, ovarian cancer clinicians should focus on the diagnosis and treatment of low muscle mass and density.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2155Subventions
Organisme : Edith Cowan University Ph.D. Scholarship
Organisme : Australian Government Research Training Program Scholarship
Organisme : Western Australian Cancer Council Ph.D. Top-up Scholarship
Informations de copyright
© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.
Références
A. J. Cruz‐Jentoft, G. Bahat, J. Bauer, et al., “Sarcopenia: Revised European Consensus on Definition and Diagnosis,” Age and Ageing 48, no. 1 (2019): 16–31, https://doi.org/10.1093/ageing/afy169.
A. J. Cruz‐Jentoft, J. P. Baeyens, J. M. Bauer, et al., “Sarcopenia: European Consensus on Definition and Diagnosis: Report of the European Working Group on Sarcopenia in Older People,” Age and Ageing 39, no. 4 (2010): 412–423, https://doi.org/10.1093/ageing/afq034.
S. Bhasin, T. G. Travison, T. M. Manini, et al., “Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium,” Journal of the American Geriatrics Society 68, no. 7 (2020): 1410–1418, https://doi.org/10.1111/jgs.16372.
L.‐K. Chen, J. Woo, P. Assantachai, et al., “Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment,” Journal of the American Medical Directors Association 21, no. 3 (2020): 300–307.e2, https://doi.org/10.1016/j.jamda.2019.12.012.
R. A. Fielding, B. Vellas, W. J. Evans, et al., “Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia,” Journal of the American Medical Directors Association 12, no. 4 (2011): 249–256, https://doi.org/10.1016/j.jamda.2011.01.003.
S. A. Studenski, K. W. Peters, D. E. Alley, et al., “The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 69, no. 5 (2014): 547–558, https://doi.org/10.1093/gerona/glu010.
A. L. Couderc, E. Liuu, P. Boudou‐Rouquette, et al., “Pre‐Therapeutic Sarcopenia Among Cancer Patients: An Up‐to‐Date Meta‐Analysis of Prevalence and Predictive Value During Cancer Treatment,” Nutrients 15, no. 5 (2023): 1193, https://doi.org/10.3390/nu15051193.
J. McGovern, R. D. Dolan, P. G. Horgan, B. J. Laird, and D. C. McMillan, “Computed Tomography‐Defined Low Skeletal Muscle Index and Density in Cancer Patients: Observations From a Systematic Review,” Journal of Cachexia, Sarcopenia and Muscle 12, no. 6 (2021): 1408–1417, https://doi.org/10.1002/jcsm.12831.
L. Hanna, K. Nguo, K. Furness, J. Porter, and C. E. Huggins, “Association Between Skeletal Muscle Mass and Quality of Life in Adults With Cancer: A Systematic Review and Meta‐Analysis,” Journal of Cachexia, Sarcopenia and Muscle 13, no. 2 (2022): 839–857, https://doi.org/10.1002/jcsm.12928.
A. M. Ryan, C. M. Prado, E. S. Sullivan, D. G. Power, and L. E. Daly, “Effects of Weight Loss and Sarcopenia on Response to Chemotherapy, Quality of Life, and Survival,” Nutrition 67–68 (2019): 110539, https://doi.org/10.1016/j.nut.2019.06.020.
L. Xia, R. Zhao, Q. Wan, et al., “Sarcopenia and Adverse Health‐Related Outcomes: An Umbrella Review of Meta‐Analyses of Observational Studies,” Cancer Medicine 9, no. 21 (2020): 7964–7978, https://doi.org/10.1002/cam4.3428.
P. C.‐M. Au, H.‐L. Li, G. K.‐Y. Lee, et al., “Sarcopenia and Mortality in Cancer: A Meta‐Analysis,” Osteoporosis and Sarcopenia 7, no. Suppl 1 (2021): S28–S33, https://doi.org/10.1016/j.afos.2021.03.002.
S. S. Shachar, G. R. Williams, H. B. Muss, and T. F. Nishijima, “Prognostic Value of Sarcopenia in Adults With Solid Tumours: A Meta‐Analysis and Systematic Review,” European Journal of Cancer & Clinical Oncology 57 (2016): 58–67, https://doi.org/10.1016/j.ejca.2015.12.030.
G. L. Jensen, T. Cederholm, M. I. T. D. Correia, et al., “GLIM Criteria for the Diagnosis of Malnutrition: A Consensus Report From the Global Clinical Nutrition Community,” JPEN Journal of Parenteral and Enteral Nutrition 43, no. 1 (2019): 32–40, https://doi.org/10.1002/jpen.1440.
K. Fearon, F. Strasser, S. D. Anker, et al., “Definition and Classification of Cancer Achexia: An International Consensus,” Lancet Oncology 12, no. 5 (2011): 489–495, https://doi.org/10.1016/S1470‐2045(10)70218‐7.
J. Ni and L. Zhang, “Cancer Cachexia: Definition, Staging, and Emerging Treatments,” Cancer Management and Research 12 (2020): 5597–5605, https://doi.org/10.2147/CMAR.S261585.
A. M. Ryan, D. G. Power, L. Daly, S. J. Cushen, Ē. Ní Bhuachalla, and C. M. Prado, “Cancer‐Associated Malnutrition, Cachexia and Sarcopenia: The Skeleton in the Hospital Closet 40 Years Later,” Proceedings of the Nutrition Society 75, no. 2 (2016): 199–211, https://doi.org/10.1017/S002966511500419X.
G. R. Williams, A. M. Deal, H. B. Muss, et al., “Skeletal Muscle Measures and Physical Function in Older Adults With Cancer: Sarcopenia or Myopenia?” Oncotarget 8, no. 20 (2017): 33658–33665, https://doi.org/10.18632/oncotarget.16866.
L. E. Daly, C. M. Prado, and A. M. Ryan, “A Window Beneath the Skin: How Computed Tomography Assessment of Body Composition Can Assist in the Identification of Hidden Wasting Conditions in Oncology That Profoundly Impact Outcomes,” Proceedings of the Nutrition Society 77, no. 2 (2018): 135–151, https://doi.org/10.1017/S0029665118000046.
N. Kiss, J. Loeliger, M. Findlay, et al., “Clinical Oncology Society of Australia: Position Statement on Cancer‐Related Malnutrition and Sarcopenia,” Nutrition and Dietetics 77, no. 4 (2020): 416–425, https://doi.org/10.1111/1747‐0080.12631.
D. Meza‐Valderrama, E. Marco, V. Dávalos‐Yerovi, et al., “Sarcopenia, Malnutrition, and Cachexia: Adapting Definitions and Terminology of Nutritional Disorders in Older People With Cancer,” Nutrients 13, no. 3 (2021): 761, https://doi.org/10.3390/nu13030761.
B. H. Goodpaster, S. W. Park, T. B. Harris, et al., “The Loss of Skeletal Muscle Strength, Mass, and Quality in Older Adults: The Health, Aging and Body Composition Study,” Journal of Gerontology 61, no. 10 (2006): 1059–1064, https://doi.org/10.1093/gerona/61.10.1059.
V. S. Armstrong, L. W. Fitzgerald, and O. F. Bathe, “Cancer‐Associated Muscle Wasting—Candidate Mechanisms and Molecular Pathways,” International Journal of Molecular Sciences 21, no. 23 (2020): 9268, https://doi.org/10.3390/ijms21239268.
C. Schofield, P. Lopez, P. A. Cohen, et al., “Skeletal Muscle Morphology in Patients Receiving Primary Versus Interval Cytoreductive Surgery for Advanced High‐Grade Serous Ovarian Cancer,” International Journal of Gynecological Cancer 33, no. 10 (2023): 1587–1594, https://doi.org/10.1136/ijgc‐2023‐004425.
A. Tranoulis, F. L. A. Kwong, A. Lakhiani, D. Georgiou, J. Yap, and J. Balega, “Prevalence of Computed Tomography‐Based Sarcopenia and the Prognostic Value of Skeletal Muscle Index and Muscle Attenuation Amongst Women With Epithelial Ovarian Malignancy: A Systematic Review and Meta‐Analysis,” European Journal of Surgical Oncology 48, no. 7 (2022): 1441–1454, https://doi.org/10.1016/j.ejso.2022.02.024.
K. A. Bruno, M. J. Sobreira da Silva, and G. V. Chaves, “Association of Body Composition With Toxicity to First‐Line Chemotherapy and Three‐Year Survival in Women With Ovarian Adenocarcinoma,” Acta Oncologica 60, no. 12 (2021): 1611–1620, https://doi.org/10.1080/0284186X.2021.1983210.
M. Del Grande, S. Rizzo, G. M. Nicolino, et al., “Computed Tomography‐Based Body Composition in Patients With Ovarian Cancer: Association With Chemotoxicity and Prognosis,” Frontiers in Oncology 11 (2021): 718815, https://doi.org/10.3389/fonc.2021.718815.
T. K. Malmstrom, D. K. Miller, E. M. Simonsick, L. Ferrucci, and J. E. Morley, “SARC‐F: A Symptom Score to Predict Persons With Sarcopenia at Risk for Poor Functional Outcomes,” Journal of Cachexia, Sarcopenia and Muscle 7, no. 1 (2016): 28–36, https://doi.org/10.1002/jcsm.12048.
C. M. M. Prado, J. R. Lieffers, L. J. McCargar, et al., “Prevalence and Clinical Implications of Sarcopenic Obesity in Patients With Solid Tumours of the Respiratory and Gastrointestinal Tracts: A Population‐Based Study,” Lancet Oncology 9, no. 7 (2008): 629–635, https://doi.org/10.1016/S1470‐2045(08)70153‐0.
S. N. Voelker, N. Michalopoulos, A. B. Maier, and E. M. Reijnierse, “Reliability and Concurrent Validity of the SARC‐F and Versions: A Systematic Review and Meta‐Analysis,” Journal of the American Medical Directors Association 22, no. 9 (2021): 1864–1876.e16, https://doi.org/10.1016/j.jamda.2021.05.011.
G. R. Williams, M. Al‐Obaidi, C. Dai, S. Bhatia, and S. Giri, “SARC‐F for Screening of Sarcopenia Among Older Adults With Cancer,” Cancer 127, no. 9 (2021): 1469–1475, https://doi.org/10.1002/cncr.33395.
T. Ichikawa, H. Miyaaki, S. Miuma, et al., “Comparison of Calculated Body Muscle Mass and SARC‐F as Methods of Screening for Sarcopenia in Patients With Chronic Liver Disease,” Biomedical Reports 14, no. 4 (2021): 34, https://doi.org/10.3892/br.2021.1410.
J. M. Siqueira, I. C. L. de Oliveira, J. D. P. Soares, and G. D. Pimentel, “SARC‐F Has Low Correlation and Reliability With Skeletal Muscle Mass Index in Older Gastrointestinal Cancer Patients,” Clinical Nutrition 40, no. 3 (2021): 890–894, https://doi.org/10.1016/j.clnu.2020.08.018.
T. G. Barbosa‐Silva, A. M. B. Menezes, R. M. Bielemann, T. K. Malmstrom, and M. C. Gonzalez, “Enhancing SARC‐F: Improving Sarcopenia Screening in the Clinical Practice,” Journal of the American Medical Directors Association 17, no. 12 (2016): 1136–1141, https://doi.org/10.1016/j.jamda.2016.08.004.
X. S. Yee, Y. S. Ng, J. C. Allen, et al., “Performance on Sit‐to‐Stand Tests in Relation to Measures of Functional Fitness and Sarcopenia Diagnosis in Community‐Dwelling Older Adults,” European Review of Aging and Physical Activity 18, no. 1 (2021): 1, https://doi.org/10.1186/s11556‐020‐00255‐5.
D. Sanchez‐Rodriguez, E. Marco, and A. J. Cruz‐Jentoft, “Defining Sarcopenia: Some Caveats and Challenges,” Current Opinion in Clinical Nutrition and Metabolic Care 23, no. 2 (2020): 127–132, https://doi.org/10.1097/MCO.0000000000000621.
K. Webber, E. Carolus, L. Mileshkin, et al., “OVQUEST—Life After the Diagnosis and Treatment of Ovarian Cancer—An International Survey of Symptoms and Concerns in Ovarian Cancer Survivors,” Gynecologic Oncology 155, no. 1 (2019): 126–134, https://doi.org/10.1016/j.ygyno.2019.08.009.
C. Stretch, J.‐M. Aubin, B. Mickiewicz, et al., “Sarcopenia and Myosteatosis Are Accompanied by Distinct Biological Profiles in Patients With Pancreatic and Periampullary Adenocarcinomas,” PLoS One 13 (2018): e0196235, https://doi.org/10.1371/journal.pone.0196235.
H. Ahn, D. W. Kim, Y. Ko, et al., “Updated Systematic Review and Meta‐Analysis on Diagnostic Issues and the Prognostic Impact of Myosteatosis: A New Paradigm Beyond Sarcopenia,” Ageing Research Reviews 70 (2021): 101398, https://doi.org/10.1016/j.arr.2021.101398.
E. van Seventer, J. P. Marquardt, A. S. Troschel, et al., “Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer,” Journal of the National Comprehensive Cancer Network 19, no. 3 (2021): 319–327, https://doi.org/10.6004/jnccn.2020.7618.